Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Petit 2018 MiP2018"

From Bioblast
Line 17: Line 17:
|organism=Human, Saccharomyces cerevisiae
|organism=Human, Saccharomyces cerevisiae
|tissues=HeLa
|tissues=HeLa
|couplingstates=OXPHOS
}}
}}
== Affiliations ==
== Affiliations ==

Revision as of 16:07, 2 August 2018

MiPsociety
Decreasing cytosolic translation is beneficial to yeast and human Tafazzin-deficient cells with dirupted mitochondrial homeostasis (Barth syndrome cell model).

Link: MiP2018

De Taffin de Tilques M, Lasserre JP, Godard F, Sardin E, Bouhier M, Le Guedard M, Kucharczyk R, Testet E, Di Rago JP, Tribouillard-Tanvier D, Petit PX (2018)

Event: MiP2018

COST Action MITOEAGLE

Cardiolipin (CL) optimizes diverse mitochondrial processes, includ-ing oxidative phosphorylation (OXPHOS). To function properly, CL needs to be unsaturated, which requires the acyltransferase Tafazzin (TAZ) [1]. Loss-of-function mutations in the TAZ gene are responsible for the Barth syndrome (BTHS), a rare X-linked cardiomyopathy, presumably because of a diminished OXPHOS capacity [2]. Herein we show that a partial inhibition of cytosolic protein synthesis, either chemically with the use of cycloheximide or by specific genetic mutations, fully restores biogenesis and the activity of the oxidative phosphorylation system in a yeast BTHS model (taz1Δ). Interestingly, the defaults in CL were not suppressed, indicating that they are not primarily responsible for the OXPHOS deficiency in taz1Δ yeast.

Low concentrations of cycloheximide in the picomolar range were beneficial to TAZ-deficient HeLa cells, as evidenced by the recovery of a good proliferative capacity. These findings reveal that a diminished capacity of CL remodeling deficient cells to preserve protein homeostasis is likely an important factor contributing to the pathogenesis of BTHS. This in turn, identifies cytosolic translation as a potential therapeutic target for the treatment of this disease [3]


Bioblast editor: Plangger M, Kandolf G


Labels: MiParea: nDNA;cell genetics  Pathology: Myopathy 

Organism: Human, Saccharomyces cerevisiae  Tissue;cell: HeLa 


Coupling state: OXPHOS 



Affiliations

De Taffin de Tilques M(2), Lasserre JP(2), Godard F, Sardin E, Bouhier M, Le Guedard M, Kucharczyk R, Testet E, Di Rago JP(2), Tribouillard-Tanvier D(2), Petit PX(1)

  1. CNRS FR3636, Inst de Neurosciences, Univ Paris-Descartes
  2. Inst de Biochimie et génétique cellulaire, CNRS UMR 5095, Univ de Bordeaux; France. - [email protected]


References

  1. Saric A, … Petit PX (2016) Front Genet 20;6:359.
  2. Gonzalvez F, … Petit PX (2013) Biochim Biophys Acta; 1832 (8): 1194-206.
  3. De Taffin de Tilques M, … Tribouillard-Tanvier D (2018) Microb Cell 18;5(5):220-32.